Core Insights - Azenta, Inc. has formed a strategic partnership with the PRECEDE Foundation to enhance early detection and prevention of pancreatic cancer [1][4] - The partnership aims to improve the five-year survival rate of pancreatic cancer from 13% to 50% within the next decade [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [8] - The company operates in North America, Europe, and Asia, with its headquarters in Burlington, Massachusetts [9] Industry Context - Pancreatic cancer is the third-leading cause of cancer-related deaths in the U.S., with over 66,500 diagnoses annually and a five-year survival rate of only 13% [2] - The PRECEDE Consortium, which includes over 60 academic medical centers, focuses on improving screening and risk modeling for individuals at hereditary risk of pancreatic cancer [3][6] Partnership Details - Azenta will provide secure storage for study samples in its biorepository, allowing PRECEDE researchers to concentrate on advancing diagnostics and patient survival [1][4] - The collaboration emphasizes Azenta's role in supporting high-impact life science research and enhancing the capabilities of biorepositories [4]